Related references
Note: Only part of the references are listed.Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer
K. Azuma et al.
ANNALS OF ONCOLOGY (2014)
Antitumor immune responses induced by ionizing irradiation and further immune stimulation
Benjamin Frey et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer
R. D. Harvey
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
Ching-Yao Yang et al.
EUROPEAN JOURNAL OF CANCER (2014)
Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
S. S. Ramalingam et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti et al.
LABORATORY INVESTIGATION (2014)
Immunotherapy in the treatment of non-small cell lung cancer
Raghav Sundar et al.
LUNG CANCER (2014)
Immune Checkpoint Blockade: The Hope for Immunotherapy as a Treatment of Lung Cancer?
Julie R. Brahmer
SEMINARS IN ONCOLOGY (2014)
Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
Yang Zhang et al.
ONCOTARGETS AND THERAPY (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Yuhui Huang et al.
CANCER RESEARCH (2013)
Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
Jennifer M. Boland et al.
CLINICAL LUNG CANCER (2013)
Harnessing the Immune System for the Treatment of Non-Small-Cell Lung Cancer
Julie R. Brahmer
JOURNAL OF CLINICAL ONCOLOGY (2013)
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Silvia C. Formenti et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Ipilimumab and Its Toxicities: A Multidisciplinary Approach
Leslie A. Fecher et al.
ONCOLOGIST (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Alterations of immune response of non-small cell lung cancer with Azacytidine
John Wrangle et al.
ONCOTARGET (2013)
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
Julie R. Brahmer et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Silica-induced Chronic Inflammation Promotes Lung Carcinogenesis in the Context of an Immunosuppressive Microenvironment
Javier Freire et al.
NEOPLASIA (2013)
Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
Esdy N. Rozali et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen et al.
CLINICAL CANCER RESEARCH (2012)
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression
Geoffrey R. Oxnard et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non-Small-Cell Lung Cancer
Leow Pay Chin et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy
Kaan Harmankaya et al.
MEDICAL ONCOLOGY (2011)
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
Chuan-Yong Mu et al.
MEDICAL ONCOLOGY (2011)
NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES
Shom Goel et al.
PHYSIOLOGICAL REVIEWS (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
W. M. Liu et al.
BRITISH JOURNAL OF CANCER (2010)
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Krithika N. Kodumudi et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions
O. Akbari et al.
MUCOSAL IMMUNOLOGY (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
Francois Romagne et al.
BLOOD (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
ALK Gene Rearrangements A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer
Benjamin Solomon et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy
Lei Zhang et al.
CLINICAL IMMUNOLOGY (2008)
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
Stephanie G. Downey et al.
CLINICAL CANCER RESEARCH (2007)
Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth
Trina J. Stewart et al.
JOURNAL OF IMMUNOLOGY (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment
C. Grande et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2007)
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients
Maher K. Gandhi et al.
BLOOD (2006)
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
E Suzuki et al.
CLINICAL CANCER RESEARCH (2005)
B7-h1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
J Konishi et al.
CLINICAL CANCER RESEARCH (2004)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
SY Tseng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)